TY - JOUR
T1 - The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms
T2 - Moving toward an effective oral, outpatient therapy
AU - Falchi, Lorenzo
AU - Verstovsek, Srdan
AU - Ravandi-Kashani, Farhad
AU - Kantarjian, Hagop M.
N1 - Publisher Copyright:
© 2015 American Cancer Society.
PY - 2016/4/15
Y1 - 2016/4/15
N2 - The therapeutic potential of arsenic derivatives has long been recognized and was recently rediscovered in modern literature. Early studies demonstrated impressive activity of this compound in patients with relapsed acute promyelocytic leukemia (APL). Over the last 2 decades, intravenous arsenic trioxide has been used successfully, both alone and in combination with other agents, for the treatment of APL and, with some success, of other myeloid neoplasms. Arsenic trioxide is currently part the standard of care for patients with APL. More recently, oral formulations of this compound have been developed and are entering clinical practice. In this review, the authors discuss the evolution of arsenic in the treatment of APL and other myeloid neoplasms. Cancer 2016;122:1160-8.
AB - The therapeutic potential of arsenic derivatives has long been recognized and was recently rediscovered in modern literature. Early studies demonstrated impressive activity of this compound in patients with relapsed acute promyelocytic leukemia (APL). Over the last 2 decades, intravenous arsenic trioxide has been used successfully, both alone and in combination with other agents, for the treatment of APL and, with some success, of other myeloid neoplasms. Arsenic trioxide is currently part the standard of care for patients with APL. More recently, oral formulations of this compound have been developed and are entering clinical practice. In this review, the authors discuss the evolution of arsenic in the treatment of APL and other myeloid neoplasms. Cancer 2016;122:1160-8.
KW - acute promyelocytic leukemia
KW - all-trans retinoic acid
KW - arsenic trioxide
KW - oral arsenic
UR - http://www.scopus.com/inward/record.url?scp=84952837775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952837775&partnerID=8YFLogxK
U2 - 10.1002/cncr.29852
DO - 10.1002/cncr.29852
M3 - Review article
C2 - 26716387
AN - SCOPUS:84952837775
SN - 0008-543X
VL - 122
SP - 1160
EP - 1168
JO - Cancer
JF - Cancer
IS - 8
ER -